Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects.
The pharmacokinetics of the anti-inflammatory drug benzydamine were determined after intravenous infusion of 5 mg to six healthy male subjects. Benzydamine was characterized as a drug of relatively low systemic clearance (ca. 160 ml min-1) but high volume of distribution (ca. 1101); the apparent terminal half-life in plasma was ca. 8 h. Benzydamine was well absorbed after oral administration, as indicated by a mean systemic availability of 87 per cent. However, absorption of the drug was low (less than 10 per cent of the dose) after its use by male subjects as a mouthwash, or after its application to female subjects as dermal cream and vaginal douche preparations. The data suggest that benzydamine is generally not well absorbed through the skin and non-specialized mucosae, thereby limiting unrequired systemic exposure to this drug when it is used by these routes.
Baldock
G A
GA
Department of Metabolism and Pharmacokinetics, Huntingdon Research Centre, Cambridgeshire, England.
Brodie
R R
RR
Chasseaud
L F
LF
Taylor
T
T
Walmsley
L M
LM
Catanese
B
B
D000279:Administration, Cutaneous; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D001591:Benzydamine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D001682:Biological Availability; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes
D009067:Mouthwashes; D001591:Benzydamine